Curbing Illicit Drug Threats Act

Bill: 118-hr-6045
Sponsor: full_name: Rep. Caraveo, Yadira [D-CO-8]
Introduced: 2023-10-25
Policy area: Health
Subjects: Congressional oversight

Drug trafficking and controlled substances

Government information and archives

Government studies and investigations

Intelligence activities, surveillance, classified information
Latest action: action_date: 2023-10-25
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2023-10-25
action_desc: Introduced in House
text: <p><b>Curbing Illicit Drug Threats Act</b></p> <p>This bill requires the Government Accountability Office to study the effectiveness of federal drug surveillance systems, such as the Drug Overdose Surveillance and Epidemiology System of the Centers for Disease Control and Prevention, in monitoring and addressing illicit drug use.</p>

tv_txt: I 118th CONGRESS 1st Session H. R. 6045 IN THE HOUSE OF REPRESENTATIVES October 25, 2023 Ms. Caraveo (for herself and Mr. Kean of New Jersey ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To direct the Comptroller General of the United States to conduct a study and submit a report on the efficacy of Federal drug surveillance systems, and for other purposes.

1. Short title This Act may be cited as the Curbing Illicit Drug Threats Act . 2. GAO study and report on efficacy of Federal drug surveillance systems (a) Study The Comptroller General of the United States shall conduct a study on— (1) the efficacy of Federal drug surveillance systems in providing up-to-date information on illicit drug use in the United States, including any limitations affecting such efficacy; and (2) how such systems are used to address illicit drug use in the United States. (b) Report Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall complete the study under subsection (a) and submit to Congress a report containing— (1) the findings and conclusions of such study; and (2) any recommendations for legislative or administrative actions to improve the efficacy of the Federal drug surveillance systems examined in such study, including any recommendations pertaining to interagency communication or data collection procedures. (c) Federal drug surveillance systems defined In this section, the term Federal drug surveillance systems includes— (1) the Drug Overdose Surveillance and Epidemiology System of the Centers for Disease Control and Prevention (commonly known as DOSE ); (2) the State Unintentional Drug Overdose Reporting System of the Centers for Disease Control and Prevention (commonly known as SUDORS ); (3) the National Drug Early Warning System of the National Institute on Drug Abuse (commonly known as NDEWS ); and (4) the Drug Abuse Warning Network of the Substance Abuse and Mental Health Services Administration (commonly known as DAWN ).